NAV

Ancestim

Identification

Summary

Ancestim is a human stem cell factor used in combination with filgrastim during autologous peripheral blood progenitor cell (PBPC) transplantation to increase PBPC mobilization for improved collection.

Generic Name
Ancestim
DrugBank Accession Number
DB09103
Background

Ancestim is a non-glycosylated recombinant methionyl human stem cell factor. It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine5. Ancestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes.2 It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.4

Type
Biotech
Groups
Approved, Investigational, Withdrawn
Biologic Classification
Protein Based Therapies
Haematopoietic growth factors
Protein Structure
Protein Chemical Formula
C1662H2650N422O512S18
Protein Average Weight
18540.0 Da (non-glycosylated)
Sequences
>>Sequence Stem Cell Factor<<<<
MEGICRNRVTNNVKDVTKLVANLPKDYMITLKYVPGMDVLPSHCWISEMVVQLSDSLTDL
LDKFSNISEGLSNYSIIDKLVNIVDDLVECVKENSSKDLKKSFKSPEPRLFTPEEFFRIF
NRSIDAFKDFVVASETSDCVVSSTLSPEKDSRVSVTKPFMLPPVA
Download FASTA Format
Synonyms
  • Ancestim

Pharmacology

Indication

Ancestim, in combination with filgrastim, is indicated for the setting of autologous peripheral blood progenitor cell transplantation in patients at risk of poor peripheral blood progenitor cell mobilisation.7 The use of ancestim with filgrastim will generate a sustained increase in the number of peripheral blood progenitor cells capable of engraftment. It is used for mobilization of progenitor cells from the bone marrow to the peripheral blood with or withouth mobilizing chemotherapy. The harvested progenitor cells can be used for transplant following myelosuppressive or myeloablative therapies.6

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Ancestim action on hemotopeitic progenitor cells stimulates its proliferation, differentiation, commitment and functional activation. This stimulation results in an increase on circulating peripheral blood progenitor cells like CD34, granulocyte macrophage colony-forming units and erythroid burst-forming units.6

Mechanism of action

Ancestim alone is unable to increase peripheral blood progenitor cells so it has to be administered with filgastrim, a granulocyte colony-stimulating factor.3 Ancestrim will bind to the c-KIT expressed in hemocytoblasts, myeloid progenitors, megakaryocytes, immature mast cells, myeloblasts and lymphoid progenitors. Ancestim binding will cause receptor homodimerization and autophosphorylation at tyrosine residues. The activation of this receptor leads to the activation of a signaling cascade that contains the RAS/ERK, PI3-Kinase, Src kinase and JAK/STAT pathways which will later stimulate proliferation, differentiation and activation of the cell lines.1

TargetActionsOrganism
AMast/stem cell growth factor receptor Kit
agonist
Humans
Absorption

The pharmacokinetics of ancestim has a dose-linear profile. After subcutaneous administration, ancestim has an absorption half-life of 35-41 hours following a mean lag of 2 hours. When a dose of 5-25 mcg/kg is administered, the peak concentration of 3.6-13.7 ng/ml is reached after 15-24 hours. In preclinical studies, the bioavailability of ancestim was reported to be greater than 60%. After multiple dosing, the steady state was reached after 4-5 days from the beginning of the treatment.6

Volume of distribution

Preclinical reports demonstrate that after intravenous administration of ancestim, the distribution profile is primarily in plasma and kidneys with a subsequent and rapid loss from all tissues.6

Protein binding

Not Available

Metabolism

Administration of ancestim in preclinical trials have proven that from the excreted dose all of it is formed by degraded ancestim into lower molecular weigth products.6

Route of elimination

In preclinical studies, it was shown that 90% of the administered dose is excreted in the urine.6

Half-life

In clinical trials, the reported half life for ancestim was between 2-5 hours.6

Clearance

The apparent clearance reported for ancestim is approximately 35-40 ml/h/kg.6

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Ancestim was not genotoxic for gene mutation or chromosomal damage and it did not have any effect in fertility.6

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbacavirAbacavir may decrease the excretion rate of Ancestim which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Ancestim which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Ancestim which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Ancestim which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Ancestim which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Ancestim which could result in a higher serum level.
AcrivastineAncestim may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Ancestim which could result in a higher serum level.
Adefovir dipivoxilAdefovir dipivoxil may decrease the excretion rate of Ancestim which could result in a higher serum level.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
StemgenAncestim (1875 mcg / vial) + Water (5 mL / vial)Kit; Powder, for solutionSubcutaneousBiovitrum Ab (Publ)1999-09-202012-12-31Canada flag
StemgenAncestim (2500 mcg / vial) + Water (5 mL / vial)Kit; Powder, for solutionSubcutaneousBiovitrum Ab (Publ)Not applicableNot applicableCanada flag

Categories

ATC Codes
L03AA12 — Ancestim
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
PYB4Q6JG41
CAS number
163545-26-4

References

General References
  1. Ronnstrand L: Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci. 2004 Oct;61(19-20):2535-48. doi: 10.1007/s00018-004-4189-6. [Article]
  2. Trahan P. (1999). Clinical Handbook for biotherapy. Jones and Bartlett Publishers Inc..
  3. Galbraith A., Bullock S., Manias E., Hunt B., and Richards A. (2013). Fundamentals of Pharmacology: An applied approach for nursing and health (2nd ed.). Pearson Education Limited. [ISBN:1741031443]
  4. Health Canada [Link]
  5. Sobi [Link]
  6. Stemgen monograph [Link]
  7. Stemgen monograph [Link]
PubChem Substance
347910405
RxNav
140502
Wikipedia
Ancestim
MSDS
Download (133 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentMultiple Myeloma (MM)1
0Unknown StatusTreatmentMyelodysplastic Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Kit; powder, for solutionSubcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)230ºC'MSDS'
boiling point (°C)520ºC at 760 mmHg'MSDS'
water solubilityInsoluble'MSDS'
isoelectric point5.86'MSDS'

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Mast/stem cell growth factor receptor Kit
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Transmembrane receptor protein tyrosine kinase activity
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell main...
Gene Name
KIT
Uniprot ID
P10721
Uniprot Name
Mast/stem cell growth factor receptor Kit
Molecular Weight
109863.655 Da
References
  1. Ronnstrand L: Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci. 2004 Oct;61(19-20):2535-48. doi: 10.1007/s00018-004-4189-6. [Article]
  2. Barnett A. (2012). Type 2 diabetes (2nd ed.). Oxford.
  3. Stemgen monograph [Link]

Drug created at September 16, 2015 22:07 / Updated at January 14, 2023 19:02